OverviewSuggest Edit

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

TypePublic
Founded2008
HQPhiladelphia, US
Websiteadaptimmune.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)400(-6%)
Job Openings54
Revenue (FY, 2019)$1.1 M(-98%)
Share Price (Oct 2020)$6.3 (-20%)
Cybersecurity ratingBMore

Key People/Management at Adaptimmune

David M. Mott

David M. Mott

Chairman
Gavin Wood

Gavin Wood

Chief Financial Officer
Lawrence M. Alleva

Lawrence M. Alleva

Non-Executive Director
Mark Dudley

Mark Dudley

Senior Vice President, Early Stage Development
Helen Tayton-Martin

Helen Tayton-Martin

Chief Business Officer
Ali Behbahani

Ali Behbahani

Non-Executive Director
Show more

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia, Milton and Stevenage
Philadelphia, US (HQ)
351 Rouse Blvd
Milton, GB
60 Jubilee Ave
Stevenage, GB
Gunnels Wood Rd
Show all (3)

Adaptimmune Financials and Metrics

Adaptimmune Revenue

Adaptimmune's revenue was reported to be $1.12 m in FY, 2019
USD

Revenue (Q2, 2020)

502.0k

Net income (Q2, 2020)

(29.9m)

EBIT (Q2, 2020)

(30.3m)

Market capitalization (16-Oct-2020)

975.6m

Closing stock price (16-Oct-2020)

6.3

Cash (30-Jun-2020)

122.4m

EV

876.5m
Adaptimmune's current market capitalization is $975.6 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

14.2m37.8m59.5m1.1m

EBIT

(72.8m)(80.7m)(82.4m)(139.8m)

EBIT margin, %

(513%)(213%)(138%)(12457%)

Interest expense

1.1m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.9m328.0k2.4m2.9m3.5m27.2m8.2m9.0m40.8m157.0k237.0k761.0k502.0k

General and administrative expense

11.8m10.1m9.3m10.3m

R&D expense

22.0m25.5m21.3m20.5m

Operating expense total

33.8m35.7m30.5m30.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

158.8m84.0m68.4m50.4m

Accounts Receivable

149.5k206.0k192.0k

Prepaid Expenses

21.7m25.8m30.9m

Inventories

1.4m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(23.0m)(70.1m)(95.5m)(137.2m)

Depreciation and Amortization

5.4m7.8m8.0m

Cash From Operating Activities

(48.2m)(54.3m)(104.4m)(112.5m)

Purchases of PP&E

(24.6m)(3.9m)(1.6m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(15.6m)(37.7m)(56.2m)(21.8m)(42.0m)(42.9m)(21.1m)(64.6m)(59.3m)(27.4m)(68.5m)(107.8m)(28.2m)(58.0m)

Depreciation and Amortization

707.0k1.5m2.3m1.0m2.2m3.7m1.9m3.8m5.7m2.0m4.0m5.9m1.7m3.6m

Accounts Payable

(2.7m)3.6m

Cash From Operating Activities

(18.7m)(35.2m)(50.5m)(28.4m)(46.4m)(33.0m)(47.3m)(82.6m)(72.7m)(36.2m)(70.4m)(100.0m)16.9m(8.1m)
USDQ1, 2016

Financial Leverage

1.2 x
Show all financial metrics

Adaptimmune Operating Metrics

FY, 2016

Patent Applications

69

Patents Issued

173
Show all operating metrics

Adaptimmune Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Adaptimmune Online and Social Media Presence

Embed Graph

Adaptimmune News and Updates

Adaptimmune Reports Q2 Financial Results and Business Update

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -

Thinking about buying stock in Tenax Therapeutics, Allena Pharmaceuticals, Trevena, Adaptimmune Therapeutics, or Aurora Cannabis?

NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TENX, ALNA, TRVN, ADAP, and ACB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?

NEW YORK, May 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

- Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 -

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”)…

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies -
Show more

Adaptimmune Blogs

Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020

- The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom , April 29, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for Q1 2020, before the U.S.

Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products Content Import Tue, 04/28/2020 - 08:01 Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union f…

Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

PHILADELPHIA and OXFORDSHIRE, United Kingdom , April 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion

Mara Goldstein

Mara Goldstein alfredo.macaba… Thu, 04/23/2020 - 09:14 Mara Goldstein Mizuho Securities USA

Gavin Wood

Gavin Wood pamleonardo Wed, 04/01/2020 - 08:36 Gavin Wood Chief Financial Officer Gavin Wood has served as our Chief Financial Officer since April 2020 and is a member of our Executive Team.  Mr. Wood has held CFO and senior management …

Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020

Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020 Content Import Thu, 02/20/2020 - 16:00 Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020 February 20, 2…
Show more

Adaptimmune Frequently Asked Questions

  • When was Adaptimmune founded?

    Adaptimmune was founded in 2008.

  • Who are Adaptimmune key executives?

    Adaptimmune's key executives are David M. Mott, Gavin Wood and Lawrence M. Alleva.

  • How many employees does Adaptimmune have?

    Adaptimmune has 400 employees.

  • What is Adaptimmune revenue?

    Latest Adaptimmune annual revenue is $1.1 m.

  • What is Adaptimmune revenue per employee?

    Latest Adaptimmune revenue per employee is $2.8 k.

  • Who are Adaptimmune competitors?

    Competitors of Adaptimmune include CosmosID, TCR2 Therapeutics and Novavax.

  • Where is Adaptimmune headquarters?

    Adaptimmune headquarters is located at 351 Rouse Blvd, Philadelphia.

  • Where are Adaptimmune offices?

    Adaptimmune has offices in Philadelphia, Milton and Stevenage.

  • How many offices does Adaptimmune have?

    Adaptimmune has 3 offices.